IFRX InflaRx GmbH: ערך חשבונאי למניה

The book value per share demonstrates the asset base of InflaRx N.V. (IFRX), where the value is fixed at 1.12, correlating with expectations for C5a-component therapy and successes in treating purulent pathologies. However, the struggle for government protocols against biotech behemoths and high costs of bringing drugs to market are temporarily constraining business margins on an investment plateau.

Patent protection for monoclonal antibodies and colossal R&D expenditures create a powerful defensive moat for InflaRx N.V. (IFRX), which determines the value of its intangible assets. This metric measures the actual asset coverage of capital, allowing investors to assess the intrinsic value of the business relative to its market price via the net asset value per share.